Eosinophil-associated diseases: the Allergist's and Clinical Immunologist's perspective.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Country of Publication: Italy NLM ID: 101466614 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1764-1489 (Print) Linking ISSN: 17641489 NLM ISO Abbreviation: Eur Ann Allergy Clin Immunol Subsets: MEDLINE
    • Publication Information:
      Publication: 2014- : Milano : EDRA LSWR
      Original Publication: Paris : Meditions Carline
    • Subject Terms:
      Eosinophils*/immunology ; Eosinophilia*/immunology ; Eosinophilia*/diagnosis ; Allergists*; Humans ; Hypereosinophilic Syndrome/diagnosis ; Hypereosinophilic Syndrome/immunology ; Hypereosinophilic Syndrome/drug therapy ; Allergy and Immunology ; Sinusitis/immunology ; Sinusitis/diagnosis
    • Abstract:
      Summary: Eosinophil-associated diseases (EADs) refer to heterogeneous conditions in which eosinophils are believed to play critical pathological roles. They encompass common respiratory conditions, such as asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), less common primary eosinophilic disorders of gastrointestinal tract, and rare conditions including eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES). A literature search was carried out in January 2024 in the MEDLINE and Scopus databases using the PubMed search engine (PubMed, National Library of Medicine, Bethesda, MD). We focused on blood eosinophilia and hypereosinophilia. A diagnostic workup is proposed. From allergist's point of view, we focused the review on 4 groups of eosinophilic disorders of specific interest. Our increased understanding of type 2 inflammation and biology has recently led to development of highly effective precision targeted therapies that are now approved for a growing number of eosinophilic disorders. Novel targeted biologics have a major impact on treatment strategies and have resulted in major advances in our understanding of the pathogenesis of these disorders. In the context of EADs, according to the heterogeneity of eosinophilic disorders a multidisciplinary approach should be adopted. Allergists and Clinical Immunologists play an important role as they have a clear understanding of the eosinophilic inflammation and the role of cytokines and are trained to recognize and characterize type 2 (T2) inflammation and its associated pathologies.
    • Contributed Indexing:
      Keywords: Eosinophilia; hypereosinophilia; eosinophilic disorders of gastrointestinal tract (EGID); eosinophilic granulomatosis with polyangiitis (EGPA); hypereosinophilic syndrome (HES)
    • Publication Date:
      Date Created: 20240328 Date Completed: 20240913 Latest Revision: 20240913
    • Publication Date:
      20240914
    • Accession Number:
      10.23822/EurAnnACI.1764-1489.339
    • Accession Number:
      38546414